lapatinib has been researched along with pd 173955 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (pd 173955) | Trials (pd 173955) | Recent Studies (post-2010) (pd 173955) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 29 | 0 | 13 |
| Protein | Taxonomy | lapatinib (IC50) | pd 173955 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0193 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.028 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.5889 | |
| Nucleophosmin | Homo sapiens (human) | 2.75 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.9199 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.028 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 0.002 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.8379 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.5928 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 1.66 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.028 | |
| Ephrin type-A receptor 2 | Homo sapiens (human) | 0.0079 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 2.75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
1 other study(ies) available for lapatinib and pd 173955
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |